首页> 外文期刊>American Journal of Physiology >Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy
【24h】

Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy

机译:增强肾DDAH-1通过腺病毒递送的表达减少ADMA和改善糖尿病肾病

获取原文
获取原文并翻译 | 示例
           

摘要

Endothelial dysfunction, characterized by reduced bioavailability of nitric oxide and increased oxidative stress, is a hallmark characteristic in diabetes and diabetic nephropathy (DN). High levels of asymmetric dimethylarginine (ADMA) are observed in several diseases including DN and are a strong prognostic marker for cardiovascular events in patients with diabetes and end-stage renal disease. ADMA, an endogenous endothelial nitric oxide synthase (NOS3) inhibitor, is selectively metabolized by dimethylarginine dimethylaminohydrolase (DDAH). Low DDAH levels have been associated with cardiac and renal dysfunction, but its effects on DN are unknown. We hypothesized that enhanced renal DDAH-1 expression would improve DN by reducing ADMA and restoring NOS3 levels. DBA/2J mice injected with multiple low doses of vehicle or streptozotocin were subsequently injected intrarenally with adenovirus expressing DDAH-1 (Ad-h-DDAH-1) or vector control [Ad-green fluorescent protein (GFP)], and mice were followed for 6 wk. Diabetes was associated with increased kidney ADMA and reduced kidney DDAH activity and DDAH-1 expression but had no effect on kidney DDAH-2 expression. Ad-GFP-treated diabetic mice showed significant increases in albuminuria, histological changes, glomerular macrophage recruitment, inflammatory cytokine and fibrotic markers, kidney ADMA levels, and urinary thiobarbituric acid reactive substances excretion as an indicator of oxidative stress, along with a significant reduction in kidney DDAH activity and kidney NOS3 mRNA compared with normal mice. In contrast, Ad-h-DDAH-1 treatment of diabetic mice reversed these effects. These data indicate, for the first time, that DDAH-1 mediates renal tissue protection in DN via the ADMA-NOS3-interaction. Enhanced renal DDAH-1 activity could be a novel therapeutic tool for treating patients with diabetes.
机译:内皮功能障碍,其特征在于减少一氧化氮的生物利用度和增加的氧化应激,是糖尿病和糖尿病肾病(DN)的标志性特征。在包括DN的几种疾病中观察到高水平的不对称二甲基尿苷(ADMA),并且是糖尿病患者和末期肾病患者心血管事件的强预后标志物。 ADMA,通过二甲基甘氨酸二甲基氨基酰氯酶(DDAH)选择性地代谢内源性内皮一氧化氮合酶(NOS3)抑制剂。低DDAH水平与心脏和肾功能不全有关,但其对DN的影响是未知的。我们假设通过减少ADMA和恢复NOS3水平,增强肾DDAH-1表达将改善DN。随后用表达DDAH-1(Ad-H-DDAH-1)或载体对照[ad-Green荧光蛋白(GFP)]的腺病毒,随后将具有多个低剂量的载体或链脲佐菌素注射的DBA / 2J鼠标,然后遵循载体对照[ad-green荧光蛋白(GFP)]和小鼠6周。糖尿病与肾脏adja增加和肾脏ddah活性和ddah-1的表达增加有关,但对肾ddah-2表达没有影响。 Ad-GFP处理的糖尿病小鼠表现出含比蛋白尿,组织学变化,肾小球巨噬细胞募集,炎症细胞因子和纤维化标记,肾DEMA水平和泌尿硫尿酸反应性物质排泄作为氧化应激的指标,以及显着减少与正常小鼠相比,肾DDAH活性和肾NOS3 mRNA。相比之下,糖尿病小鼠的Ad-H-DDAH-1治疗逆转了这些效果。这些数据首次表明DDAH-1通过ADMA-NOS3相互作用在DN中介导肾组织保护。增强的肾DDAH-1活性可能是一种用于治疗糖尿病患者的新型治疗工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号